FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2580493818> ?p ?o ?g. }

• W2580493818 endingPage "909" @default.
• W2580493818 startingPage "903" @default.
• W2580493818 abstract "Histone deacetylase inhibitors are members of a class of epigenetic drugs that have proven activity in T-cell malignancies, but little is known about their efficacy in B-cell lymphomas. Abexinostat is an orally available hydroxamate-containing histone deacetylase inhibitor that differs from approved inhibitors; its unique pharmacokinetic profile and oral dosing schedule, twice daily four hours apart, allows for continuous exposure at concentrations required to efficiently kill tumor cells. In this phase II study, patients with relapsed/refractory non-Hodgkin lymphoma or chronic lymphocytic leukemia received oral abexinostat at 80 mg BID for 14 days of a 21-day cycle and continued until progressive disease or unacceptable toxicity. A total of 100 patients with B-cell malignancies and T-cell lymphomas were enrolled between October 2011 and July 2014. All patients received at least one dose of study drug. Primary reasons for discontinuation included progressive disease (56%) and adverse events (25%). Grade 3 or over adverse events and any serious adverse events were reported in 88% and 73% of patients, respectively. The most frequently reported grade 3 or over treatment-emergent related adverse events were thrombocytopenia (80%), neutropenia (27%), and anemia (12%). Among the 87 patients evaluable for efficacy, overall response rate was 28% (complete response 5%), with highest responses observed in patients with follicular lymphoma (overall response rate 56%), T-cell lymphoma (overall response rate 40%), and diffuse large B-cell lymphoma (overall response rate 31%). Further investigation of the safety and efficacy of abexinostat in follicular lymphoma, T-cell lymphoma, and diffuse large B-cell lymphoma implementing a less dose-intense week-on-week-off schedule is warranted. (Trial registered at: EudraCT-2009-013691-47)." @default.
• W2580493818 created "2017-02-03" @default.
• W2580493818 creator A5003105021 @default.
• W2580493818 creator A5012342629 @default.
• W2580493818 creator A5021322016 @default.
• W2580493818 creator A5022075377 @default.
• W2580493818 creator A5023792802 @default.
• W2580493818 creator A5032462496 @default.
• W2580493818 creator A5038565847 @default.
• W2580493818 creator A5038667383 @default.
• W2580493818 creator A5051605599 @default.
• W2580493818 creator A5054416214 @default.
• W2580493818 creator A5055012214 @default.
• W2580493818 creator A5058095468 @default.
• W2580493818 creator A5071885891 @default.
• W2580493818 creator A5081516283 @default.
• W2580493818 creator A5088946428 @default.
• W2580493818 date "2017-01-25" @default.
• W2580493818 modified "2023-10-16" @default.
• W2580493818 title "Safety and efficacy of abexinostat, a pan-histone deacetylase inhibitor, in non-Hodgkin lymphoma and chronic lymphocytic leukemia: results of a phase II study" @default.
• W2580493818 cites W1991376723 @default.
• W2580493818 cites W2011664887 @default.
• W2580493818 cites W2014847708 @default.
• W2580493818 cites W2027171343 @default.
• W2580493818 cites W2032757134 @default.
• W2580493818 cites W2070433411 @default.
• W2580493818 cites W2092476693 @default.
• W2580493818 cites W2096367061 @default.
• W2580493818 cites W2097856894 @default.
• W2580493818 cites W2102685625 @default.
• W2580493818 cites W2106357158 @default.
• W2580493818 cites W2109716912 @default.
• W2580493818 cites W2110957729 @default.
• W2580493818 cites W2115593774 @default.
• W2580493818 cites W2127352480 @default.
• W2580493818 cites W2133201432 @default.
• W2580493818 cites W2142099365 @default.
• W2580493818 cites W2145940442 @default.
• W2580493818 cites W2148471976 @default.
• W2580493818 cites W2155591026 @default.
• W2580493818 cites W2156517973 @default.
• W2580493818 cites W2160457008 @default.
• W2580493818 cites W2165638033 @default.
• W2580493818 cites W2171365282 @default.
• W2580493818 cites W2484616545 @default.
• W2580493818 cites W44229036 @default.
• W2580493818 doi "https://doi.org/10.3324/haematol.2016.154377" @default.
• W2580493818 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5477609" @default.
• W2580493818 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28126962" @default.
• W2580493818 hasPublicationYear "2017" @default.
• W2580493818 type Work @default.
• W2580493818 sameAs 2580493818 @default.
• W2580493818 citedByCount "60" @default.
• W2580493818 countsByYear W25804938182016 @default.
• W2580493818 countsByYear W25804938182018 @default.
• W2580493818 countsByYear W25804938182019 @default.
• W2580493818 countsByYear W25804938182020 @default.
• W2580493818 countsByYear W25804938182021 @default.
• W2580493818 countsByYear W25804938182022 @default.
• W2580493818 countsByYear W25804938182023 @default.
• W2580493818 crossrefType "journal-article" @default.
• W2580493818 hasAuthorship W2580493818A5003105021 @default.
• W2580493818 hasAuthorship W2580493818A5012342629 @default.
• W2580493818 hasAuthorship W2580493818A5021322016 @default.
• W2580493818 hasAuthorship W2580493818A5022075377 @default.
• W2580493818 hasAuthorship W2580493818A5023792802 @default.
• W2580493818 hasAuthorship W2580493818A5032462496 @default.
• W2580493818 hasAuthorship W2580493818A5038565847 @default.
• W2580493818 hasAuthorship W2580493818A5038667383 @default.
• W2580493818 hasAuthorship W2580493818A5051605599 @default.
• W2580493818 hasAuthorship W2580493818A5054416214 @default.
• W2580493818 hasAuthorship W2580493818A5055012214 @default.
• W2580493818 hasAuthorship W2580493818A5058095468 @default.
• W2580493818 hasAuthorship W2580493818A5071885891 @default.
• W2580493818 hasAuthorship W2580493818A5081516283 @default.
• W2580493818 hasAuthorship W2580493818A5088946428 @default.
• W2580493818 hasBestOaLocation W25804938181 @default.
• W2580493818 hasConcept C104317684 @default.
• W2580493818 hasConcept C126322002 @default.
• W2580493818 hasConcept C143998085 @default.
• W2580493818 hasConcept C197934379 @default.
• W2580493818 hasConcept C203014093 @default.
• W2580493818 hasConcept C2776202225 @default.
• W2580493818 hasConcept C2776694085 @default.
• W2580493818 hasConcept C2777058707 @default.
• W2580493818 hasConcept C2777063308 @default.
• W2580493818 hasConcept C2777938653 @default.
• W2580493818 hasConcept C2778305200 @default.
• W2580493818 hasConcept C2778461978 @default.
• W2580493818 hasConcept C2778715236 @default.
• W2580493818 hasConcept C2779338263 @default.
• W2580493818 hasConcept C55493867 @default.
• W2580493818 hasConcept C64927066 @default.
• W2580493818 hasConcept C71924100 @default.
• W2580493818 hasConcept C86803240 @default.
• W2580493818 hasConcept C90924648 @default.
• W2580493818 hasConcept C98274493 @default.
• W2580493818 hasConceptScore W2580493818C104317684 @default.

• next